Cogent Biosciences, Inc.
$32.26
+0.19%Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -12.7).
Valuation inputs: P/E -12.7, earnings yield N/A, momentum +0.2%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -51.7%, ROIC -38.1%).
Profitability stack: net margin 0.0%, ROE -51.7%, ROIC -38.1%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +32.1%, momentum +0.2%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Cogent Biosciences, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Cogent Biosciences, Inc. Fair Value Envelope
Cogent Biosciences, Inc. Profit Bridge
Profitability Analysis
Cogent Biosciences, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cogent Biosciences, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Cogent Biosciences, Inc. Street Expectations Map
Wall Street analysts project that COGT stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 49.17, with estimates ranging from a low of 35.00 to a high of 60.00.
The consensus 1-year price target stands at 49.17, with estimates ranging from a low of 35.00 to a high of 60.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Analyst Conviction
Bearish or uncertain outlook. Limited upside or poor consensus suggests challenges ahead or fundamental concerns.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Cogent Biosciences, Inc. Insider Positioning
During the last 12 months, insiders have purchased $25.00M and sold $382.20M worth of COGT shares, resulting in $357.20M of net selling activity.
3 Months
0
0.00
7.0M
242.62M
-242.6M
-$242.62M
3-6 Months
0
0.00
3.8M
139.58M
-139.6M
-$139.58M
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
2.8M
25.00M
0
0.00
+25.0M
+$25.00M
Top Buyers
Fairmount Funds Management Llc
Director
$25.00M
Top Sellers
Fairmount Funds Management Llc
Director
$370.02M
Robinson John Edward
Officer: Chief Scientific Officer
$3.49M
Sachs Jessica
Officer: Chief Medical Officer
$3.20M
Green John L.
Officer: Chief Financial Officer
$2.98M
Kearns Evan
Officer: Chief Legal Officer
$2.52M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $357.20M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
COGT has not reported any dividend yield values in the available annual periods.
cogt Dividend History
Learning Layer
Related Guides
Build conviction on COGT by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.